ClinicalTrials.gg
CompletedNCT03427268Updated May 24, 2021Results posted

Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment

A Phase 2 interventional study of PM060184 in Advanced Colorectal Cancer, sponsored by PharmaMar. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-24.

Sponsored by PharmaMar · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Enrollment
365th of 405
32 · median 167
Started
2018
with 24 others
Phase 2
120 of 463
15 open now
Registered
198th of 463
by date

Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 365th largest by enrollment of the 405 interventional ones that give a count, is one of 25 that started in 2018, is one of 120 in phase 2, and was the 198th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown status) progressing after standard treatments (fluoropyrimidine, irinotecan, and oxaliplatin).

Patients in this trial will receive PM060184 at a dose of 9.3 mg/m2 as a 30-minute intravenous (i.v.) infusion on Days 1 and 8 q3wk.

03

Conditions studied

  • Advanced Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily written , obtained before the beginning of any study-specific procedures.
  2. Age ≥ 18 years.
  3. Histologically- documented adenocarcinoma of colon or rectum that has progressed to the last prior treatment before inclusion.
  4. according to (RECIST) v.1.1. If the only tumor lesion is situated in a previously irradiated area or in an area subjected to other loco-regional therapy, regression in the lesion must be demonstrated radiologically.
  5. Previous treatment in any setting with fluoropyrimidine, oxaliplatin and irinotecan in any combination (unless any is ).

    1. chemotherapy-based treatments count as prior therapy, as long as relapse had occurred during or within six months of completion of such therapies.
    2. Cumulative dose of prior oxaliplatin (if any) must be known.
    3. Prior cetuximab, panitumumab, bevacizumab, aflibercept, and regorafenib are allowed.
  6. No more than two prior therapies for disease.
  7. for prior therapies (defined in relation to planned start of study treatment [first dose administration]):

    1. At least three weeks since the last administration of an antineoplastic treatment (chemotherapy, biological, targeted or therapies).
    2. At least three weeks since radiotherapy involving up to 35% of bone marrow (radiotherapy involving > 35% of bone marrow is not allowed) or two weeks since the end of palliative radiotherapy including single doses.
    3. At least four weeks since any major surgical procedure, open , or significant traumatic injury.
  8. (ECOG) performance status (PS) 0 or 1.
  9. ≥ 3 months.
  10. Adequate bone marrow, liver, and kidney function:

    1. ≥ 9 g/dL.
    2. ≥ 1.5 × 109/L.
    3. count ≥ 100 × 109/L.
    4. Serum creatinine ≤ 1.5 mg/dL or calculated ≥ 40 mL/min (Cockcroft-Gault formula).
    5. Albumin ≥ 2.5 g/dL.
    6. Total serum ≤ 1.5 times the (ULN), except in case of Gilbert syndrome.
    7. (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5.0 × ULN in the case of liver metastases).
  11. Recovery to grade ≤ 1 from any toxicity due to previous therapy (including peripheral sensory/motor neuropathy but excluding alopecia).
  12. (LVEF) by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).
  13. Evidence of non-childbearing status for women of (WOCBP). WOCBP must agree to use a highly effective measure during the trial and up to six months after treatment discontinuation, and fertile male patients must agree to refrain from fathering a child or donating sperm during the trial and up to four months after treatment discontinuation.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Prior exposure to PM060184.
  2. Known to the study drug class or study drug in the formulation.
  3. Patients with locally advanced disease amenable to local and/or curative therapy (surgery or radiotherapy) at study entry.
  4. Other serious and/or relevant diseases or clinical situations that, in the opinion of the Investigator, are incompatible with the protocol (including any of the following):

    1. History of another neoplastic disease (except for basal cell carcinoma of the skin, superficial bladder tumors, or properly treated carcinoma in situ of the uterine cervix or melanoma in situ) unless in remission for at least five years and with no recurrence.
    2. Symptomatic cerebral and/or , spinal cord compression or carcinomatous meningitis.
    3. Neuropathy of any etiology (other than that caused by previous antineoplastic therapy).
    4. History of cardiac disease, such as myocardial infarction, in the year prior to registration in the clinical trial; symptomatic/uncontrolled angina pectoris; congestive heart failure or uncontrolled cardiac ischemia; any type of uncontrolled arrhythmia, congenital and/or prolonged or abnormal , or uncontrolled arterial hypertension (according to the standards of the World Health Organization [WHO]).
    5. History of significant psychiatric disease.
    6. Active infection requiring antibiotic, antifungal or antiviral treatment that, in the opinion of the Investigator, could compromise the patient's capacity to tolerate the therapy.
    7. Known active liver ( or C or cirrhosis) or renal disease.
    8. Known (HIV) infection.
    9. Any other concomitant pathology that could jeopardize the patient's safety or commitment to complete the clinical trial.
    10. Inability or refusal to comply with the protocol or with the clinical trial procedures.
  5. Pregnancy or lactation.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    PM060184

    PM060184

    Drug: PM060184

Interventions

  • PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point. PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle).

06

What researchers measure

Primary outcomes

  1. Progression-free Survival Rate at Three Months

    Progression-free survival rate at 12 weeks (PFS3), defined as the rate estimate of the percentage of patients who are alive and progression-free at 12 weeks (\~3 months) after the first treatment administration. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: Time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation, up to 3 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS), defined as the time from the first day of treatment to the date of death or last contact.

    Time frame: From the first day of treatment to the date of death or last contact, up to 12 months

  2. Progression Free Survival (PFS)

    Progression-free survival (PFS), defined as the time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation, up to 12 months

  3. Overall Response Rate (ORR)

    Overall Response Rate defined as the percentage of patients with either complete response (CR) or partial response (PR) according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; RECIST, Response Evaluation Criteria in Solid Tumors

    Time frame: Time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation, up to 12 months

07

Results

Posted May 24, 2021

Participant flow

The first informed consent was signed on 16 January 2018 and the first study treatment administration was on 8 February 2018. The cutoff date for the results was 11 February 2019 (date of last follow-up).

Participant flow — Overall Study
MilestonePM060184
Started32
Completed0
Not completed32
Withdrew: Progressive disease25
Withdrew: Never treated2
Withdrew: Compassionate use1
Withdrew: Withdrawal by subject1
Withdrew: Adverse event3

Outcome measures

PrimaryProgression-free Survival Rate at Three Months

Progression-free survival rate at 12 weeks (PFS3), defined as the rate estimate of the percentage of patients who are alive and progression-free at 12 weeks (\~3 months) after the first treatment administration. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
Time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation, up to 3 months
Reported as:
Number · percentage of participants
Progression-free Survival Rate at Three Months
percentage of participantsPM060184
Progression-free Survival Rate at Three Months20.7 (8 to 39.7)
SecondaryOverall Survival (OS)

Overall Survival (OS), defined as the time from the first day of treatment to the date of death or last contact.

Time frame:
From the first day of treatment to the date of death or last contact, up to 12 months
Reported as:
Median · months
Overall Survival (OS)
monthsPM060184
Overall Survival (OS)9.8 (4.6 to NA)
SecondaryProgression Free Survival (PFS)

Progression-free survival (PFS), defined as the time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation, up to 12 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPM060184
Progression Free Survival (PFS)2.6 (1.3 to 2.8)
SecondaryOverall Response Rate (ORR)

Overall Response Rate defined as the percentage of patients with either complete response (CR) or partial response (PR) according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; RECIST, Response Evaluation Criteria in Solid Tumors

Time frame:
Time from the first day of study treatment to the day of assessment of progression, death or last tumor evaluation, up to 12 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsPM060184
SD <3 months9
SD ≥3 months7
PD13

Adverse events

Collected over Patients were assessed between study start date and study completion date, approximately 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PM06018416/30 (53.3%)6/30 (20%)30/30 (100%)
Most frequent serious events
Most frequent serious events
EventPM060184
Alanine aminotransferase increasedInvestigations3/30
Aspartate aminotransferase increasedInvestigations3/30
Blood bilirubin increasedInvestigations1/30
Febrile neutropeniaBlood and lymphatic system disorders1/30
PyrexiaGeneral disorders1/30
Abdominal painGastrointestinal disorders1/30
DiarrhoeaGastrointestinal disorders1/30
Pneumonia pneumococcalInfections and infestations1/30
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPM060184
AstheniaGeneral disorders22/30
Abdominal painGastrointestinal disorders20/30
ConstipationGastrointestinal disorders19/30
ParaesthesiaNervous system disorders14/30
AlopeciaSkin and subcutaneous tissue disorders14/30
DiarrhoeaGastrointestinal disorders11/30
Decreased appetiteMetabolism and nutrition disorders10/30
NauseaGastrointestinal disorders9/30
AnaemiaBlood and lymphatic system disorders7/30
PyrexiaGeneral disorders5/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PM060184
<=18 years0
Between 18 and 65 years23
>=65 years9
Age, Continuous
Age, Continuous(years)PM060184
Median62 (36 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)PM060184
Female17
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PM060184
White32
Region of Enrollment
Region of Enrollment(Participants)PM060184
Canada1
Spain31
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(Participants)PM060184
PS 015
PS 117
Stage at diagnosis
Stage at diagnosis(Participants)PM060184
Stage I1
Stage IIIB5
Stage IIIC2
Stage IV17
Stage IVA3
Stage IVB3
UK1
Primary tumor side
Primary tumor side(Participants)PM060184
Left22
Right10

15 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • US017
    Los Angeles, California 90089-9181, United States
  • CA001
    Toronto, Ontario ON M5G 2M9, Canada
  • ES001
    Barcelona, 08035, Spain
  • ES009
    Madrid, 28041, Spain
  • ES002
    Valencia, 46010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Feb 2019, 12 months.

Results were first posted in May 2021, 2 years 3 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 12 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Feb 9, 2018
StartActual
Jan 16, 2018
Primary completionActual
Feb 11, 2019
CompletionActual
Feb 11, 2019
Results first posted
May 24, 2021
Last update
May 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03427268
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Jan 16, 2018
Primary completion
Feb 11, 2019
Completion
Feb 11, 2019
Results posted
May 24, 2021
Last update
May 24, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plocabulin

Start the discussion